Press Release · Press Releases
PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. NEW YORK, Oct. 27, 2026 /PRNewswire/ -- Leading...
This press release summary is reproduced from the issuer's public feed.
Read the full release at PR NewswireOriginal publisher: PR Newswire
Spotted an error? Request a correction · Corrections Policy
Related stories
Invesco Reports Results for the Three Months Ended September 30, 2026
Invesco Announces Third Quarter Diluted EPS of $0.65; Adjusted Diluted EPS (1) of $0.72 ATLANTA, Oct. 27, 2026 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ) today reported financial results for the three months ended September 30, 2026. $35.1 billion of net long-term inflows for the quarter,...
PR Newswire ·
Bybit Partners with XAUE Protocol to Offer 2.83% Fixed APR on XAUT Savings
DUBAI, UAE, Oct. 27, 2026 /PRNewswire/ -- Bybit, the New Financial Platform trusted by more than 80 million users worldwide, is pleased to launch a new fixed-term XAUT Savings offering in partnership with XAUE Protocol. On Bybit Easy Earn, eligible holders of Tether Gold (XAUT) will...
PR Newswire ·
Johnson Controls Reports Q4 and FY26 Results; Initiates FY27 Guidance
Q4 sales increased 10% and organic sales increased 12%* Q4 GAAP EPS of $1.60; Q4 Adjusted EPS* of $1.66* Q4 orders +44% organically year-over-year Backlog of $23.0 billion increased 43% organically year-over-year * This earnings release contains non-GAAP financial measures. Definitions...
PR Newswire ·
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6%...
PR Newswire ·
Hodinky HUAWEI WATCH D3, poprvé představené na konferenci ISH-ECS 2026, přinášejí pokročilé monitorování krevního tlaku do každodenního života
DUBAJ, Spojené arabské emiráty, 27. října 2026 /PRNewswire/ -- Ve dnech 22. až 25. října 2026 se v Dubaji konalo 31. vědecké zasedání Mezinárodní společnosti pro hypertenzi a 17. výroční konference Emirátské kardiologické společnosti (ISH-ECS 2026). Jako významné mezinárodní zasedání...
PR Newswire ·
ECOVACS WINBOT W3 OMNI unter den „Best Inventions of 2026“ des TIME-Magazins
NEW YORK, 27. Oktober 2026 /PRNewswire/ -- ECOVACS ROBOTICS, ein weltweit führender Anbieter im Bereich der Haushaltsrobotik, gibt mit Stolz bekannt, dass sein WINBOT W3 OMNI in die Liste der „Best Inventions of 2026" des TIME-Magazins aufgenommen wurde[1]. Diese Auszeichnung...
PR Newswire ·